Objective. To compare baseline characteristics, responses and drug survival in patients with early RA starting SSZ or MTX in a real-life setting.
Introduction
RA is a chronic inflammatory disease with a potentially disabling outcome, and it is widely accepted that early diagnosis and early institution of treatment with DMARDs is paramount to prevent joint damage and achieve the lowest possible disease activity state [1, 2] . Both SSZ and MTX have documented efficacy on signs and symptoms in patients with RA [35] . Two randomized controlled trials (RCTs) on DMARD-naïve patients with early RA have shown similar clinical responses with SSZ and MTX, but the MTX doses used were relatively low (up to 15 mg/week) [6, 7] . A 5-year observational study showed similar clinical responses of SSZ and MTX, but less erosive progression in the MTX group [8] . Several studies have shown that the use of MTX has increased since the 1980s, and that, more recently, the relative use of SSZ vs MTX has declined [811] .
The most recent treatment recommendations from the European League Against Rheumatism (EULAR) state that MTX should be (part of) the first treatment strategy for patients with active RA; SSZ is mentioned as an alternative drug for patients in whom MTX is contraindicated [1] . MTX and SSZ are also listed as possible first-line therapies in the most recent recommendations from the American College of Rheumatology (ACR) [12] . While the ACR recommends MTX as first-line therapy in all scenarios, irrespective of disease activity level and prognostic factors, SSZ is generally only recommended for patients without unfavourable prognostic markers and with a low to moderate disease activity level [12] .
There is a lack of recent studies on the comparative effectiveness of SSZ and MTX in an era where treatment practice has changed with both the introduction of biologic DMARDs and a stronger focus on early and aggressive treatment. The objective of this study was to compare demographics, baseline characteristics, clinical responses and retention to therapy in DMARD-naïve patients with early RA starting SSZ or MTX, who have been included in an ongoing longitudinal observational study in Norway over the past decade.
Methods

Setting and patients
Data for this study were provided by the NOR-DMARD register, which includes adult patients with inflammatory arthropathies starting treatment with synthetic and/or biological DMARDs in five Norwegian rheumatology departments. The register covers approximately1.4 million people (one-third of the Norwegian population) and is set up as a longitudinal observational study with assessments at baseline, after 3, 6 and 12 months and yearly thereafter. The study was conducted with approval by the Regional Ethics Committee of South-Eastern Norway and the Data Inspectorate. Patients gave written informed consent before participation.
For the current study, we included DMARD-naïve patients with RA with disease duration of 41 year, enrolled in the NOR-DMARD register between December 2000 and May 2009 and starting treatment with SSZ or MTX as monotherapies. The diagnosis of RA was made by the treating rheumatologist based on clinical judgement. At the time of analysis, follow-up data until February 2010 were available. For the effectiveness analyses we included 3-and 6-month follow-up data, and analysis of drug survival was based on 3-year data with censoring of patients with inadequate follow-up time and patients who were lost to follow-up.
Assessments and outcomes
Assessments included 28 swollen joint count (28-SJC) and 28 tender joint count (28-TJC) performed by rheumatologists or trained research nurses, ESR, CRP, 0100 mm visual analogue scales (VASs) for physician's assessment of global disease activity and patient's assessment of joint pain, fatigue and global disease activity (100 mm = worst score), and the modified HAQ (MHAQ) [13] . Further, patients completed the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) questionnaire [14, 15] which was used to calculate physical component summary (SF-36 PCS) and mental component summary scores (SF-36 MCS) and SF-6D [16] . The 28-joint DAS (DAS-28) with ESR [17] , the simplified disease activity index (SDAI) [18] and the proportions achieving EULAR good response [19] and DAS-28 remission (DAS-28 < 2.6) were calculated. We also applied the ACR response criteria (ACR20, ACR50 and ACR70 responses) [20] as well as the recently published ACR/ EULAR remission criteria, both the Boolean-and the index-based definition (SDAI 4 3.3) [21, 22] . To account for differences in retention to therapy, we calculated LUNDEX values for each response and remission category at 3 and 6 months by the following formula: LUNDEX value = (fraction of starters still in study at time T) Â (fraction responding at time T) [23] . Information about dates of and reasons for treatment discontinuation was systematically recorded.
Statistical analysis
Continuous variables are presented as means (S.D.) if normally distributed and medians [interquartile ranges (IQRs)] if non-normally distributed. Independent-samples t-test and MannWhitney U-test were applied as appropriate. Dichotomous variables are presented as frequencies and percentages and were compared by chi-square test. For continuous variables, we compared the 3-and 6-month completer data, and in addition we used the last observation carried forward (LOCF) approach to replace missing 6-month data with data from the 3-month assessment if available.
A priori we suspected that there would be differences in demographics and baseline disease activity, which might have influenced the treating physicians' decision to treat with SSZ or MTX (i.e. confounding by indication), and we calculated propensity scores for each patient to be able to at least partially adjust for this source of bias [8, 24, 25] . The propensity score was calculated by multivariate logistic regression with treatment (SSZ vs MTX) as the dependent variable and age, sex, centre, RF status, baseline prednisolone use and baseline DAS-28 as covariates. The propensity scores were divided into quintiles, and the balance of demographics and baseline disease activity across treatment groups within each quintile was checked [25] . Further details are available in the supplementary data, available at Rheumatology Online.
We then applied analysis of covariance (ANCOVA) with the changes in outcome measures as the dependent variables and treatment (SSZ vs MTX) and propensity score quintile as factors. For the changes which were not normally distributed, we used the van der Waerden normal scores of the changes instead of the changes themselves. Finally, 3-year retention to therapy (drug survival) was compared by KaplanMeier analysis and Cox regression analysis with adjustment for propensity score quintile.
In addition to the comparison of the full cohorts of patients on SSZ and MTX, we performed 1 : 1 matching of patients based on RF status and baseline disease activity (measured by Statistical tests were two-sided, P < 0.05 was considered statistically significant and no correction for multiple testing was made. Statistical analyses were performed using the Predictive Analytics Software (PASW) program, version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
Overall, 1102 patients, of whom 175 (15.9%) were started on SSZ and 927 (84.1%) on MTX, fulfilled the inclusion criteria for these analyses. Other treatments than SSZ and MTX (HCQ n = 38, synthetic DMARD combinations n = 26, TNF inhibitors n = 24, LEF n = 15, sodium aurothimalate n = 6 and auranofin n = 4) for this group of patients were excluded from the analyses.
SSZ-treated patients were somewhat younger and more often RF negative than patients started on MTX ( Table 1 At baseline, patients started on MTX scored significantly worse for most disease measures (Table 1) , with mean DAS-28 of 5.00 vs 4.38 for patients started on SSZ (P < 0.001). Further, MTX-treated patients had a higher number of swollen joints (Table 1) , but the distribution of joint swelling (large vs small joints, upper vs lower extremities, symmetry) did not differ (data not shown). Baseline data are shown both for all included patients and for patients with available 3-and/or 6-month data included in the effectiveness analyses, and the results were very similar (Table 1) .
Medication
For patients treated with SSZ, mean (S.D.) SSZ dose was 1.8 (0.5) g at baseline, 2.0 (0.5) g at 3 months and 2.1 (0.4) g at 6 months, with a median (IQR) dose of 2.0 (2.02.0) g at all time points. Mean (S.D.)/median (IQR) doses of MTX were 11.6 (3.6)/10 (7.515) mg at baseline, 14.4 (3.9)/15 (12.515) mg at 3 months, and 15.1 (4.2)/15 (12.520) mg at 6 months. At baseline, prednisolone was used by 32.0% of SSZ-and 55.6% of MTX-treated patients (P < 0.001), with mean doses of 8.4 and 9.4 mg (P = 0.10), respectively. At 3 months, 21.9/49.0% (P < 0.001) of patients on SSZ/MTZ used prednisolone in doses of 6.0/6.2 mg (P = 0.69), and the respective numbers at 6 months were 16.9/41.5% (P < 0.001) and 5.6/5.7 mg (P = 0.91). The proportions that received IA CS injections were similar for SSZ-and MTX-treated patients at baseline, 3 and 6 months.
Propensity scores
Fit of the propensity score model was satisfactory (HosmerLemeshow goodness-of-fit test P = 0.35). Adding more variables to the propensity score model reduced the model fit substantially. The mean/median propensity scores in each group as well as distribution of patients across propensity score quintiles are shown in Table S1 , available as supplementary data at Rheumatology online. All baseline characteristics in Table 1 , except for the physician global VAS, were balanced within each quintile (data not shown). We therefore performed a sensitivity analysis where we included the physician global as an independent variable in addition to the propensity score quintile.
Changes in disease measures
Patients treated with MTX showed numerically larger improvement in all disease measures at 6 months using the LOCF approach (Table 2 ). Mean ÁDAS-28 was À1.04 for SSZ vs À1.52 for MTX (P = 0.003). The statistical significance of many of the differences was not maintained when adjusting for propensity score quintile (Table 2) . Similar results were observed for the 3 and 6 months as observed data (Table S2 , available as supplementary data at Rheumatology Online). The difference between groups was greater at 3 than 6 months, possibly reflecting that more patients discontinued SSZ than MTX due to lack of efficacy (LOE) between 3 and 6 months (see details below). Adjusting for baseline, physician global in addition to propensity score quintile generally resulted in only minor changes in P-values, with a statistically significant difference in favour of MTX for a minority of the outcomes (Table 2 and Table S2 , available supplementary data at Rheumatology Online).
Response and remission rates
Three-and 6-month response and remission rates are presented in Table 3 . At 3 months, MTX-treated patients showed higher response and remission rates by all criteria, and the differences in ACR response and SDAI remission rates were statistically significant (Table 3) . ACR50 response was achieved by 8.7 vs 22.6% of patients treated with SSZ and MTZ, respectively, while 6.3 vs 12.9% achieved SDAI remission. Applying the LUNDEX formula the corresponding numbers were 5.9 vs 21.3% for ACR50 and 4.3 vs 12.1% for SDAI remission due to fewer patients on SSZ (69%) than on MTX (94%) still on therapy at 3 months. As observed for the change scores, differences in crude response rates were less pronounced at 6 months, and statistically significant superior response for MTX over SSZ was only seen for the ACR20 response (51.8 vs 37.2%, P = 0.01) ( Table 3) . Of the patients assessed at 6 months, the DAS-28 remission rate was actually significantly higher for SSZ (44.7%) than for MTX (32.5%) (P = 0.03), while all LUNDEX-adjusted response and remission rates were superior for MTX since far more patients on MTX (86%) than on SSZ (56%) remained on therapy for 56 months (Table 3) . changes in disease measures (LOCF for missing data) were generally numerically superior for MTX, but most differences did not reach statistical significance (Table 4) . Response rates and LUNDEX values for matched patients are shown in Table S3 (available as supplementary data at Rheumatology Online), and drug survival is compared in Fig. S1 (available as supplementary data at Rheumatology Online). Further details are given in the supplementary data, available at Rheumatology Online.
Discussion
In this register-based real-life study including DMARDnaïve patients with early RA, MTX was much more commonly used than SSZ, which is in line with the recent EULAR recommendations for treatment of RA [1] .
Patients started on SSZ were more often RF negative and had, on average, lower disease activity when starting therapy. The unadjusted 3-and 6-month effectiveness and 3-year retention to therapy were superior for MTX. Several placebo-controlled randomized trials published in the 1980s and 1990s showed that MTX reduced signs and symptoms of RA, but all these trials included patients with long-standing disease who had failed on other DMARDs [4] . During the same period, the efficacy of SSZ was established through several placebo-controlled randomized trials, including patients with and without previous use of DMARDs and both early and long-standing disease [3] . MTX has gradually become the most-used first-line DMARD in RA [10] , and has also been found to be associated with reduced mortality in RA [26] . RCTs on biological DMARDs in RA have shown that the efficacy of biologics is increased when combined with MTX, and this observation has also been important to establish MTX as the cornerstone in the treatment of RA [2730] . The main difference between SSZ and MTX in this study was retention to therapy, which was far superior for MTX, both in the short (36 months) and long (3 years) term. Further, the retention rate at 5 years was only 20% for SSZ and 46% for MTX. The superior retention rate with MTX implies greater effectiveness and less serious side effect problems and is in line with previous studies comparing retention rates of different DMARDs in various RA populations [8, 3133] However, a number of patients continued to use either SSZ or MTX even if they were not in remission or a low disease activity state, which would have been the current treatment goal according to the Treat-to-Target recommendations [34] .
The frequency of AEs on SSZ vs MTX treatment in this study was relatively similar. However, the percentage of patients discontinuing therapy due to AEs was higher for SSZ than for MTX. This would suggest that the side effects that patients experienced on SSZ were more severe or problematic for them, and/or that the tolerance for side effects was inherently less with SSZ than with MTX. The latter could be due to less experienced (and expected) benefit from treatment as well as the availability of other treatment options. Further, we analysed the influence of LOE and AEs on drug survival separately (censoring patients discontinuing the drug due to other reasons), and we found that the benefit of MTX vs SSZ was highly significant for discontinuations due to both LOE and AEs, but relatively greater for AEs (log-rank P < 0.001 for both, chi-square statistic 19.5 vs 80.3). Drug survival will always be influenced by the expectations both of patients and treating physicians as well as the treatment context, including the availability of biologic DMARDs.
In this study, patients on SSZ had generally less severe disease (lower DAS-28 and less use of prednisolone) and more favourable prognostic factors (RF negative). This is different from the study by Hider et al. [8] and more in line with the findings in a recent study from the UK by Rachapalli et al. [35] and an observational study by Aletaha et al. [31] (the latter included not only DMARD-naïve patients and not only early RA). The group receiving SSZ in our study may thus be relatively representative for RA patients who might be considered candidates for initial therapy with SSZ in light of the most recent treatment recommendations [1, 12] .
The diagnosis of RA in this study was made by clinical judgement and based on the 1987 ACR classification criteria for RA [36] , but fulfilment of the criteria was not systematically checked since the case record form did not include questions about each of the seven items of these criteria. Further, it would have been of interest to be able to classify the patients retrospectively according to the recent ACR/EULAR RA classification criteria [37] , but this was not possible as we did not have information about complete 66/68-joint counts and the levels of RF and anti-CCP. There is a possibility that the RA diagnoses were less certain in the patients prescribed with SSZ and that these patients might have features related to the spondyloarthritis entity. If so, this could have influenced the treating physicians' choice of SSZ over MTX, and further explain some of the observed differences in demographics and baseline characteristics as well as have influenced the effectiveness results. As mentioned, we found no difference in joint distribution, but a lower frequency of swollen joints in all joint areas for patients prescribed with SSZ. Also, comorbidities and contraindications might have influenced the choice of first DMARD.
We used propensity score adjustment as well as a matching for disease activity and RF status to account for indication bias in this study. Neither method will be fully able to adjust for the differences between patient groups due to confounding by indication. There will likely be sources of bias not captured by the registered variables, and the statistical adjustment will generally be imperfect. Propensity score adjustment has previously been used in a similar manner in observational studies in RA [8, 24] . The adjustment for propensity score quintile reduced the statistical difference between treatment groups for all outcomes, and the effect was particularly strong for DAS-28, which is a consequence of its inclusion in the propensity score. There is the risk of overadjustment as well as under-adjustment with this approach, and results should be interpreted with some caution.
The percentage that used systemic CSs differed between groups, which is a potential source of bias. We partially accounted for this by including baseline prednisolone use in the propensity score model. Prednisolone was tapered in both groups between baseline and 6 months, but relatively more patients treated with SSZ stopped taking prednisolone, and this may have influenced the effectiveness results. The mean/median doses of MTX in this study were lower than the target dose by modern standards [1, 38] , which may have resulted in reduced effectiveness of MTX. However, the current doses were higher than those used in the trials by Haagsma et al. [6] and Dougados et al. [7] as well as in the observational study by Aletaha et al. [31] .
More patients on SSZ than on MTX discontinued therapy within the first 6 months and this difference influenced the effectiveness results since patients with a good response are more likely to remain on therapy. The LOCF approach is commonly used to replace missing data, but has obvious limitations and certain prerequisites which are seldom met in clinical studies [39] . Still, we applied this method in this study to get a better impression of 6-month effectiveness in a situation with rather large differences in retention to therapy between the groups. The LUNDEX is a suggested tool combining response rates and retentions rates [23] , and we believe that the LUNDEX values presented in Table 3 gives a more true picture of the effectiveness of SSZ than the crude response and remission rates, especially at 6 months.
Systematic radiographs of hands and feet were not part of the data collection in this study, and thus we cannot provide data on the relative benefit of MTX vs SSZ regarding radiographic progression. Both SSZ and MTX have been shown to reduce radiographic progression, but the evidence is generally considered to be stronger for MTX [4043] .
Despite the differences in baseline characteristics for patients treated with SSZ and MTX in this study, the observed superior effectiveness and retention rates for MTX further support the ideas that MTX is the first-line DMARD in RA, and that SSZ should mainly be considered for patients in whom MTX is contraindicated.
Rheumatology key messages
. DMARD-naïve RA patients prescribed with SSZ had lower disease activity than patients receiving MTX. . Effectiveness and drug survival were superior with MTX vs SSZ as first DMARD in RA.
